Evogene Ltd. (EVGN)

Evogene Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Revenue	3.85	5.58	2.98
Revenue Growth (YoY)	-30.91%	87.02%	-
Cost of Revenue	4.09	2.38	1.49
Gross Profit	-0.24	3.2	1.49
Selling, General & Admin	5.76	8.98	7.53
Research & Development	7.99	12.51	16.2
Other Operating Expenses	0.04	0.51	-
Total Operating Expenses	13.79	22	23.72
Operating Income	-14.03	-18.8	-22.23
Interest Income	2.51	7.39	1.21
Interest Expense	-1.93	-3.36	-0.93
Other Non-Operating Income (Expense)	-0.04	-0.04	-
Total Non-Operating Income (Expense)	0.54	4	0.29
Pretax Income	-13.5	-14.81	-21.95
Provision for Income Taxes	0	0.01	0.02
Net Income	-8.49	-16.49	-23.88
Minority Interest in Earnings	0.66	-1.57	-2.08
Earnings From Discontinued Operations	5.67	-3.24	-3.99
Net Income to Common	-8.49	-16.49	-23.88
Shares Outstanding (Basic)	8	6	5
Shares Outstanding (Diluted)	8	6	5
Shares Change (YoY)	38.21%	24.14%	-
EPS (Basic)	-1.08	-2.90	-5.20
EPS (Diluted)	-1.08	-2.90	-5.20
Shares Outstanding	8.72	6.51	5.08
Free Cash Flow	-13.64	-20.33	-22.15
Free Cash Flow Per Share	-1.73	-3.57	-4.83
Gross Margin	-6.25%	57.32%	50.03%
Operating Margin	-364.24%	-337.17%	-745.51%
Profit Margin	-350.35%	-265.68%	-736.59%
FCF Margin	-353.93%	-364.46%	-742.92%
EBITDA	-12.89	-17.42	-20.93
EBITDA Margin	-334.55%	-312.41%	-701.91%
EBIT	-14.03	-18.8	-22.23
EBIT Margin	-364.24%	-337.17%	-745.51%
Effective Tax Rate	-0.01%	-0.06%	-0.09%

Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q